Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00665925

Public ClinicalTrials.gov record NCT00665925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) inhibitor, R935788 (R788), at a dose of 100 mg, orally, twice-a-day, and/or a dose of of 150 mg, orally, once-a-day is effective in the treatment of Rheumatoid Arthrits in patients who have had an inadequate clinical response to methotrexate.

Study identification

NCT ID
NCT00665925
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rigel Pharmaceuticals
Industry
Enrollment
457 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
May 31, 2009
Completion
May 31, 2009
Last update posted
Sep 15, 2016

2008 – 2009

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
Divison of Rheumatology Allergy and Immunology La Jolla California 92037
Desert Medical Advances Palm Desert California 92260
Arthritis & Osteoporosis Center, PC Hamden Connecticut 06518
Cynthia Morgan Washington D.C. District of Columbia 20003
Florida Medical Research Institute Gainsville Florida 32607
Paddock Park Clinical Research Ocala Florida 34474
Jeffrey Poiley, MD Orlando Florida 32804
Lovelace Scientific Resources Sarasota Florida 34233
Rheumatology Associates, SC Chicago Illinois 60612
Memorial Medical Group Clinical Research Inst South Bend Indiana 46601
Center for Arthritis & Osteoporosis Elizabethtown Kentucky 42701
The Osteoporosis & Clinical Trials Center Hagerstown Maryland 21740
Fiechtner Research, Inc. Lansing Michigan 48910
Westroads Medical Group Omaha Nebraska 68114
North Carolina Arthritis & Allergy Care Center Raleigh North Carolina 27609
Wake Forest University Winston-Salem North Carolina 27157
Health Research of Oklahoma Oklahoma City Oklahoma 73103
Rheumatology Associates Erie Pennsylvania 16508
Clinical Research Center of Reading, LLP West Reading Pennsylvania 19611
Rheumatic Disease Associates Willow Grove Pennsylvania 19090
Rheumatology Associates Charleston South Carolina 29407
Austin Rheumatology & Research Austin Texas 78705
Arthritis Center of South Texas San Antonio Texas 78232
Arthritis Northwest, PLLC Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00665925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00665925 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →